| 0 (0%) | 05-31 09:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 268.3 |
1-year : | 275.05 |
| Resists | First : | 229.71 |
Second : | 235.49 |
| Pivot price | 228.45  |
|||
| Supports | First : | 220.36 |
Second : | 183.34 |
| MAs | MA(5) : | 230.38 |
MA(20) : | 227.54 |
| MA(100) : | 232.32 |
MA(250) : | 199.96 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 57.9 |
D(3) : | 67.7 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 251.71 | Low : | 146.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ JNJ ] has closed above bottom band by 28.9%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 231.76 - 233.21 | 233.21 - 234.23 |
| Low: | 221.17 - 222.97 | 222.97 - 224.24 |
| Close: | 222.98 - 225.6 | 225.6 - 227.45 |
Sun, 31 May 2026
J&J study suggests earlier use of prostate cancer drug improves outcomes (JNJ:NYSE) - Seeking Alpha
Sun, 31 May 2026
New J&J drug combo delays extra prostate cancer treatment by years - Stock Titan
Sun, 31 May 2026
MUFG Securities EMEA plc Purchases 195,912 Shares of Johnson & Johnson $JNJ - MarketBeat
Sat, 30 May 2026
Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally - Yahoo Finance
Fri, 29 May 2026
JNJ Reports Nearly 3.5 Years Median Survival In Lung Cancer Study - Stocktwits
Fri, 29 May 2026
Johnson & Johnson defeats heart-pump patent claims in US trial - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,400 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 22,350 (K) |
| Shares Short P.Month | 22,270 (K) |
| EPS | 8.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.74 |
| Profit Margin | 21.8 % |
| Operating Margin | 27.4 % |
| Return on Assets (ttm) | 8.4 % |
| Return on Equity (ttm) | 26.4 % |
| Qtrly Rev. Growth | 9.8 % |
| Gross Profit (p.s.) | 27.2 |
| Sales Per Share | 39.98 |
| EBITDA (p.s.) | 14.24 |
| Qtrly Earnings Growth | -53 % |
| Operating Cash Flow | 22,870 (M) |
| Levered Free Cash Flow | 12,510 (M) |
| PE Ratio | 26.07 |
| PEG Ratio | 3 |
| Price to Book value | 6.67 |
| Price to Sales | 5.63 |
| Price to Cash Flow | 23.74 |
| Dividend | 1.29 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|